Oppenheimer notes that a short report published on January 10 alleged TransMedics (TMDX) to be an operation “engaged in fraudulent billing, extortion, and organ-trafficking,” so over the past three weeks the firm has conducted numerous calls with surgeons and industry contacts. The firm’s checks did not find evidence supporting key allegations in the short report, says the analyst, who has an Outperform rating and $125 price target on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics says claims made by Scorpion Capital ‘have no merit’
- TransMedics named as short idea with $0 target by Scorpion Capital
- TransMedics down 10% to $65.39 after Scorpion Capital short report
- TransMedics downgraded to Neutral from Overweight at JPMorgan
- TransMedics price target lowered to $120 from $150 at Baird